GENE ONLINE|News &
Opinion
Blog

2021-07-30| Asia-Pacific

Takeda Signs New Deal with PeptiDream Spending Billions to Develop Neuromuscular Disease Drugs

by Kathy Huang
Share To

Neuromuscular diseases affect muscle and nerve functions in varying degrees, and the disease progression is primarily unstoppable. As a result, many drugmakers focusing on neurosciences have evolved in recent years. Takeda is one such company that holds neuromuscular diseases as a key strategic area for its growth.

On July 27th, the Japanese pharma giant announced its collaboration with PeptiDream to develop peptide drugs for neuromuscular diseases. According to the agreement, Peptiment will receive an undisclosed upfront payment and milestone payments from Takeda worth up to $3.5 billion.

 

Expanding Takeda-PeptiDream Collaboration

The main obstacle in developing neuroscience drugs is to transfer them into patients’ brains or neural systems. Last December, Takeda and PeptiDream initiated a collaboration to advance peptide-drug conjugates (PDCs) targeting central nervous system diseases to overcome the barrier.

PeptiDream’s proprietary TfR1 binding technology is a novel peptide-drug conjugator for neuromuscular diseases. Takeda uses the TfR1 binding peptide ligands to transport its neural disease drugs across the blood-brain barrier. The tech is an improvement of existing transferring techniques, wherein it can reach the neuromuscular junction that lies beyond the protection of the blood-brain barrier. Also, it promotes enhanced tissue distribution of the drugs.

 

Takeda’s Recent Investments into Neuroscience

Takeda has actively expanded its neuroscience pipelines over the past months. In March, it secured global rights to treatments for rare diseases, Dravet Syndrome and Lennox-Gastaut Syndrome from Ovid Therapeutics. The investigational treatment, soticlestat, was originally discovered at Takeda’s research center.

In the same month, Takeda entered a five-program collaboration with BridGene Biosciences to discover small molecule drugs for undruggable neurodegenerative diseases. The deal is potentially worth more than $500 million.

Related article: Takeda to Pursue Hard-to-Drug Neurodegenerative Disease Targets with BridGene Biosciences

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
R&D
New Study Reveals Hope for Recovery of Patients with Spinal Cord Injury
2022-05-27
Aspen Neuroscience Rakes in $147.5 Million for Parkinson’s Cell Therapy Development
2022-05-10
M&A
Shanghai’s Hasten Seals $322 Million Acquisition of Takeda Drugs
2022-04-06
LATEST
Flagship-Backed ProFound Launches With $75 Million to Discover Human Proteins
2022-05-27
Janssen’s First Cell Therapy Gets Europe’s Approval for Multiple Myeloma
2022-05-27
Cell and Gene Therapy Landscape in Japan is Moving Beyond Oncology
2022-05-27
New Study Reveals Hope for Recovery of Patients with Spinal Cord Injury
2022-05-27
Laekna Therapeutics Announces Dosing of First Patients in the U.S. and China in Phase Ib/III Study of Afuresertib in Combination with Fulvestrant in HR+/HER2- Breast Cancer
2022-05-26
Stanford Touts Remote-Controllable CAR-T Cell Therapy
2022-05-26
Phenomix Launches The First Obesity Biobank Registry To Study Underling Phenotypes
2022-05-26
EVENT
2022-06-03
ASCO Annual Meeting
Online and on-side
2022-06-07
Digital RESI June
Online
2022-06-09
Medhospafrica
Africa
2022-06-13
BIO International Convention
San Diego, CA
2022-12-14
BIOHK2022
Hong Kong, China
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!